Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | ICMT | O60725 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4380278 | 0.91 | HPGD (0.42) | PTGER1PTGER4PTGER3PTGER2NPC1 | |
| SCHEMBL4389711 | 0.83 | CYP4F2 (0.41) | LRRK2FFAR1MRGPRX4PTGER1PTGER4 | |
| SCHEMBL4385840 | 0.82 | MAPT (0.39) | LRRK2FFAR1MRGPRX4PTGER1PTGER4 | |
| SCHEMBL4383171 | 0.81 | PTGER1 (0.48) | FFAR1MRGPRX4PTGER1PTGER4PTGER3 | |
| SCHEMBL4379880 | 0.79 | EGFR (0.42) | NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4386765 | 0.79 | SMPD1 (0.44) | LRRK2NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4380214 | 0.79 | SGMS2 (0.43) | FFAR1MRGPRX4NPC1HPGDRAB9A | |
| SCHEMBL4384794 | 0.78 | PLA2G2A (0.41) | PTGER1PTGER4PTGER3PTGER2NPC1 | |
| SCHEMBL4379731 | 0.78 | ESR1 (0.38) | — | |
| SCHEMBL8896993 | 0.76 | MCL1 (0.47) | LRRK2FFAR1MRGPRX4PTGER1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538241-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070155813-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1704856-A1 | HSP90 FAMILY PROTEIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155813-A1 | Hsp90 family protein inhibitors | HSP90AB1, HEATR1, HSP90AB2P | LRRK2 1952/4885FFAR1 1445/4885MRGPRX4 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.